Prof. Andreas Ladurner

Company: Eisbach Bio

Job title: Chief Scientific Officer, Co-Founder & Co-Managing Director

Seminars:

Translating ALC1 Inhibition into Clinical Success: Targeting Genomic Instability 11:00 am

Leveraging EIS-12656 to disrupt chromatin remodeling and exploit vulnerabilities in tumors with impaired DNA repair mechanisms Demonstrating rapid tumor inhibition and strong tolerability in preclinical models Highlighting the drug’s translational potentialRead more

day: Day Two